StockIQpro
NASDAQ:ATYR

aTYR PHARMA INC

Track all markets on TradingView
Track all markets on TradingView

aTYR PHARMA INC's revenue fell 19.1% in fiscal 2025 to $190,000 while operating margin fell to −40856.3%, its lowest in 4 years. Free cash flow was −$62.1M, −32664.7% of revenue, and the diluted share count rose 25.2%.Summary generated from aTYR PHARMA INC's SEC filings. Latest annual report filed Mar 5, 2026.

Key statistics

Fiscal 2025 from SEC filings. Methodology
Revenue (FY25)$190,000
Revenue growth−19.1%
Revenue, 5-yr CAGR−55.1%
Gross marginn/a
Operating margin−40856.3%
Net margin−39009.5%
ROICn/a
Return on equity−107.8%
Debt / equityn/a
Free cash flow−$62.1M
FCF margin−32664.7%
Share count change+25.2%

Financials

Fiscal years, $M
Item20212022202320242025
Revenue010000
Operating income−34−46−55−68−78
Net income−34−45−50−64−74
Free cash flow−33−44−37−69−62

Recent filings

From SEC EDGAR

Peers

Biological products, (no diagnostic substances)